Durect’s Larsucosterol Receives FDA Breakthrough Therapy Designation for Severe Alcohol-Associated Hepatitis

May 22, 2024 - By admin

Moving forward, Durect plans on incorporating feedback from the FDA in the design of a Phase III trial.